2m 2m 2m 2m 2m 2m 2m
CELLDEX THERAPTC (CLDX)
NASDAQ
$32.97-$0.44 (-1.33%)
Price as of Jun 23, 2026 6:30 PM EDT- $2.6BMarket Cap
- 63.85%1-Year Change
- BiotechnologyIndustry
CELLDEX THERAPTC (CLDX)
$32.97-$0.44 (-1.33%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 97,000 -98.62% | 7.0M +1.99% | 6.9M +192.02% | 2.4M -49.32% | |
Cost of Revenue | 200,000 0.00% | 200,000 -33.33% | 300,000 +200.00% | 100,000 0.00% | |
Gross Profit | -103,000 -101.51% | 6.8M +3.60% | 6.6M +191.67% | 2.3M -50.41% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -245.1M +49.85% | -163.6M +38.59% | -118.0M +43.46% | -82.3M +54.30% | |
Depreciation and Amortization Expense | 3.4M +6.39% | 3.2M +5.62% | 3.0M +3.87% | 2.9M -5.61% | |
Total Operating Expenses | 288.9M +42.96% | 202.1M +25.20% | 161.4M +37.28% | 117.6M +54.94% | |
Operating Profit | -287.4M +47.31% | -195.1M +26.23% | -154.5M +34.11% | -115.2M +61.75% | |
Interest Income | 28.6M -23.12% | 37.2M +183.80% | 13.1M +350.77% | 2.9M +476.04% | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 28.6M -23.12% | 37.2M +183.80% | 13.1M +350.77% | 2.9M +476.04% | |
Total Nonoperating Income and Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Income before Taxes | -287.4M +82.04% | -157.9M +11.62% | -141.4M +25.91% | -112.3M +58.79% | |
Income Taxes | 0 +100.00% | -15.4M +6,673.13% | -227,000 0.00% | -227,000 0.00% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -258.8M +63.91% | -157.9M +11.62% | -141.4M +25.91% | -112.3M +59.30% | |
Net Income from Continuing Operations Applicable to Common | -258.8M +63.91% | -157.9M +11.62% | -141.4M +25.91% | -112.3M +59.30% | |
Basic EPS and Net Income | -3.90 +59.18% | -2.45 -16.10% | -2.92 +21.67% | -2.40 +46.34% | |
Diluted EPS and Net Income | -3.90 +59.18% | -2.45 -16.10% | -2.92 +21.67% | -2.40 +46.34% | |
Basic Weighted Average Shares | 66.4M +103,047.76% | 64,395 +32.91% | 48,449 +3.33% | 46,888 +9.37% | |
Diluted Weighted Average Shares | 66.4M +103,047.76% | 64,395 +32.91% | 48,449 +3.33% | 46,888 +9.37% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 28.9M +1.82% | 28.4M -18.55% | 34.8M +18.30% | 29.4M -24.82% | |
Short-Term Investments | 489.7M -29.73% | 696.9M +79.26% | 388.8M +41.11% | 275.5M -25.35% | |
Cash and Cash Equivalents and Short-Term Investments | 518.6M -28.50% | 725.3M +71.22% | 423.6M +38.91% | 305.0M -25.30% | |
Total Current Assets | 534.7M -28.44% | 747.2M +73.08% | 431.7M +35.88% | 317.7M -22.67% | |
Accumulated Depreciation | 23.9M +1.88% | 23.5M +4.82% | 22.4M +3.51% | 21.6M +2.37% | |
Property and Plant and Equipment and Net | 5.3M +22.73% | 4.3M +7.04% | 4.1M +8.35% | 3.7M +5.52% | |
Total Long-Term Assets | 13.4M +37.05% | 9.7M +9,009.35% | 107,000 +2.88% | 104,000 0.00% | |
Total Assets | 583.0M -26.42% | 792.3M +70.17% | 465.6M +32.00% | 352.7M -20.67% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 51.0M +29.09% | 39.5M +26.91% | 31.1M +67.25% | 18.6M +12.60% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 4.0M +16.41% | 3.5M -21.12% | 4.4M -17.44% | 5.3M -27.48% | |
Total Liabilities | 55.8M +23.12% | 45.3M +24.36% | 36.5M +37.41% | 26.5M +5.37% | |
Retained Earnings | -1.8B +16.64% | -1.6B +11.30% | -1.4B +11.26% | -1.3B +9.82% | |
Total Stockholders Equity | 527.2M -29.43% | 747.0M +74.06% | 429.2M +31.57% | 326.2M -22.24% | |
Total Shares Outstanding | 66.5M +0.26% | 66.4M +18.77% | 55.9M +18.40% | 47.2M +1.01% | |
Cash Flow | |||||
Cash from Operating Activities | -210.9M +33.70% | -157.8M +47.06% | -107.3M +3.43% | -103.7M +70.31% | |
Capital Expenditures | 2.7M +41.43% | 1.9M +5.56% | 1.8M -0.55% | 1.8M +46.36% | |
Cash from Investing Activities | 209.1M +172.06% | -290.1M +174.27% | -105.8M -217.61% | 89.9M +141.61% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 2.4M -99.46% | 441.4M +102.07% | 218.5M +5,259.62% | 4.1M -98.50% | |
Financials Ratio | |||||
Gross Margin | -106.19% -209.30% | 97.15% +1.58% | 95.64% -0.12% | 95.76% -2.14% | |
Operating Margin | -296,254.64% +10,560.90% | -2,778.89% +23.77% | -2,245.27% -54.08% | -4,889.01% +219.17% | |
Return on Assets | -37.63% +49.93% | -25.10% -27.39% | -34.56% +22.68% | -28.17% +35.95% | |
Return on Equity | -40.62% +51.31% | -26.84% -28.31% | -37.45% +24.29% | -30.13% +34.34% | |
Revenue Growth | -98.62% -5,054.69% | 1.99% -98.96% | 192.02% +489.32% | -49.32% +32.23% | |
Current Ratio | 10.49 -44.56% | 18.91 +36.38% | 13.87 -18.75% | 17.07 -31.32% | |
Cash Ratio | 0.57 -21.13% | 0.72 -35.82% | 1.12 -29.27% | 1.58 -33.23% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow